Neutral tumor evolution?

The PCAWG Evolution and Heterogeneity Working Group

doi:10.1038/s41588-018-0258-x

Neutral tumor evolution?

The PCAWG Evolution and Heterogeneity Working Group

Department of Statistics

Research output: Contribution to journal › Letter › peer-review

43 Citations (Scopus)

Original language	English
Pages (from-to)	1630-1633
Number of pages	4
Journal	Nature Genetics
Volume	50
Issue number	12
DOIs	https://doi.org/10.1038/s41588-018-0258-x
Publication status	Published - 2018 Dec 1

Bibliographical note

Funding Information:
This work was supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001202), the UK Medical Research Council (FC001202) and the Wellcome Trust (FC001202) (M.T. and P.V.L.). M.T. is supported as a postdoctoral fellow by the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie Grant agreement no. 747852-SIOMICS). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation’s support toward the establishment of The Francis Crick Institute. I.M. is funded by a Cancer Research UK Career Development Fellowship (C57387/A21777). D.C.W. is funded by the Li Ka Shing Foundation. This work was supported by grant 1U24CA210957 to P.T.S.. F.M. acknowledges support from the University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited. Parts of this work were funded by Cancer Research UK core grant C14303/A17197 (F.M.). This project was enabled through access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the UK Medical Research Council (grant no. MR/ L016311/1) (M.T. and P.V.L.). Parts of the results published here are based on data generated by the TCGA Research Network (http://cancergenome.nih.gov/).

Funding Information:
A.S. is supported by the Chris Rokos Fellowship in Evolution and Cancer and by Cancer Research UK (A22909). T.A.G. is supported by Cancer Research UK (A19771). C.P.B. is supported by the Wellcome Trust (097319/Z/11/Z). B.W. is supported by a Geoffrey W. Lewis Post-Doctoral Training fellowship. A.S. and T.A.G. are jointly supported by the Wellcome Trust (202778/B/16/Z and 202778/Z/16/Z, respectively). This work was also supported by Wellcome Trust funding to the Centre for Evolution and Cancer (105104/Z/14/Z).

ASJC Scopus subject areas

Genetics

Access to Document

10.1038/s41588-018-0258-x

Cite this

@article{51e8d3c86f0141f8beedd96b54252950,

title = "Neutral tumor evolution?",

author = "{The PCAWG Evolution and Heterogeneity Working Group} and Maxime Tarabichi and I{\~n}igo Martincorena and Moritz Gerstung and Leroi, {Armand M.} and Florian Markowetz and Dentro, {Stefan C.} and Ignaty Leshchiner and Clemency Jolly and Kerstin Haase and Jeff Wintersinger and Deshwar, {Amit G.} and Kaixian Yu and Santiago Gonzalez and Yulia Rubanova and Geoff Macintyre and Adams, {David J.} and Pavana Anur and Rameen Beroukhim and Boutros, {Paul C.} and Bowtell, {David D.} and Campbell, {Peter J.} and Shaolong Cao and Christie, {Elizabeth L.} and Marek Cmero and Yupeng Cun and Dawson, {Kevin J.} and Jonas Demeulemeester and Nilgun Donmez and Drews, {Ruben M.} and Roland Eils and Yu Fan and Matthew Fittall and Garsed, {Dale W.} and Gad Getz and Gavin Ha and Marcin Imielinski and Lara Jerman and Yuan Ji and Kortine Kleinheinz and Juhee Lee and Henry Lee-Six and Livitz, {Dimitri G.} and Salem Malikic and Mitchell, {Thomas J.} and Ville Mustonen and Layla Oesper and Martin Peifer and Myron Peto and Raphael, {Benjamin J.} and Shin, {Seung Jun}",

note = "Funding Information: This work was supported by The Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001202), the UK Medical Research Council (FC001202) and the Wellcome Trust (FC001202) (M.T. and P.V.L.). M.T. is supported as a postdoctoral fellow by the European Union{\textquoteright}s Horizon 2020 research and innovation program (Marie Sk{\l}odowska-Curie Grant agreement no. 747852-SIOMICS). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation{\textquoteright}s support toward the establishment of The Francis Crick Institute. I.M. is funded by a Cancer Research UK Career Development Fellowship (C57387/A21777). D.C.W. is funded by the Li Ka Shing Foundation. This work was supported by grant 1U24CA210957 to P.T.S.. F.M. acknowledges support from the University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited. Parts of this work were funded by Cancer Research UK core grant C14303/A17197 (F.M.). This project was enabled through access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the UK Medical Research Council (grant no. MR/ L016311/1) (M.T. and P.V.L.). Parts of the results published here are based on data generated by the TCGA Research Network (http://cancergenome.nih.gov/). Funding Information: A.S. is supported by the Chris Rokos Fellowship in Evolution and Cancer and by Cancer Research UK (A22909). T.A.G. is supported by Cancer Research UK (A19771). C.P.B. is supported by the Wellcome Trust (097319/Z/11/Z). B.W. is supported by a Geoffrey W. Lewis Post-Doctoral Training fellowship. A.S. and T.A.G. are jointly supported by the Wellcome Trust (202778/B/16/Z and 202778/Z/16/Z, respectively). This work was also supported by Wellcome Trust funding to the Centre for Evolution and Cancer (105104/Z/14/Z).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41588-018-0258-x",

language = "English",

volume = "50",

pages = "1630--1633",

journal = "Nature Genetics",

issn = "1061-4036",